Condition (MeSH)
Hemangiopericytoma
ClinicalTrials.gov lists 7 trials for Hemangiopericytoma or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
6 of the 7 trials are tagged with Hemangiopericytoma itself; the rest are tagged with a narrower condition beneath it.
When did Hemangiopericytoma trials start? (6)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1/2
- Phase 2
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 1 |
| 2020 | 1 |
| 2018 | 2 |
| 2010 | 1 |
| 2007 | 1 |
| 2001 | 1 |
No forecast is made for this condition: it averages 0.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 7 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Hemangiopericytoma trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1/2 | 1 |
| Phase 2 | 3 |
| Observational | 3 |
How many Hemangiopericytoma trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 4 |
| Terminated | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Hemangiopericytoma trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| Novartis Pharmaceuticals | 1 |
Which serious adverse events do Hemangiopericytoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Dyspnea | 34 | 1 |
| Pleural effusion | 30 | 1 |
| Nausea | 18 | 1 |
| Musculo. Pain | 17 | 1 |
| Vomiting | 17 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Hemangiopericytoma? (11)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. | Cancer | 2011 | Yes |
| Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour. | Investigational new drugs | 2010 | Yes |
| A reappraisal of hemangiopericytoma of bone; analysis of cases reclassified as synovial sarcoma and solitary fibrous tumor of bone. | The American journal of surgical pathology | 2010 | Yes |
| Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma. | Neurosurgery | 2008 | Yes |
| Management of recurrent meningeal hemangiopericytoma. | Cancer | 1998 | Yes |
Showing 5 of 11 publications.
Prevalence (2)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Solitary fibrous tumor | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Solitary fibrous tumor | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Solitary fibrous tumor | 2126 | Exact | Orphadata Science knowledge files, Product 1 |
| Solitary fibrous tumor | 2126 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (1)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Not computed for conditions with fewer than 10 trials: drugs tested.